
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a strong performance in Q2 2025, surpassing expectations in both revenue and earnings, while also increasing full-year guidance, indicating robust operational health. The company experienced a significant 60% quarter-over-quarter sales growth for Mounjaro in international markets, bolstered by new product launches in regions such as Brazil, Mexico, and India. Moreover, the anticipated introduction of orforglipron presents a compelling addition to the GLP-1 market, enhancing Eli Lilly's portfolio with an oral weight loss option that aligns with patient preferences.
Bears say
The financial outlook for Eli Lilly is negatively impacted by several key risks, including potential pricing pressures and a subpar prescription trajectory for tirzepatide, which may not meet performance expectations. Additionally, the company has identified a decline in Zepbound prescriptions, which is anticipated to hinder volumetric growth in the upcoming quarter. Furthermore, heightened competition from drugs such as orforglipron poses a significant threat to Lilly's market share, as it is expected to disrupt existing revenue streams, particularly in the cardiometabolic segment.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares